NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Montara Therapeutics

Montara Therapeutics

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://montaratx.com/

Last Round

Grant

Jun 2, 2026

Total Funding Raised

$32.3M

Company Overview

Montara Therapeutics is a biotechnology company that develops brain-selective therapies for central nervous system diseases using its proprietary BrainOnly™ platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoveryprecision medicineneurosciencecentral nervous systemCNStargeted therapydrug delivery platformpreclinical drug developmentneurodegenerative diseasebiopharmatherapeutic indexcombination therapybrain-selective pharmacologyundruggable targets

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Montara Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Montara Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Montara Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 2, 2026
GrantMay 21, 2025
SeedMar 13, 2025
SeedJul 30, 2024
SeedJan 19, 2024

Key People

Founding team and executive leadership

Nicholas Hertz

President Chief Executive Officer

Executive Team

Zachary Hill

Chief Technology Officer

Executive Team

Montara Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 8, 2025

    Partnering with the TSC Alliance to advance lead program.

  • Dec 8, 2025

    Initial data on MT1110-everolimus combination presented at AES Annual Meeting.

Montara Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Montara Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Montara Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range25
Year Founded2024
Last FundingJun 2, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.